Evaluation of macrolides for possible use against multidrug-resistant *Mycobacterium tuberculosis*

Anne-Fleur van der Paardt, Bob Wilffert, Onno W. Akkerman, Wiel C.M. de Lange, Dick van Soolingen, Bhanu Sinha, Tjip S. van der Werf, Jos G.W. Kosterink, Jan-Willem C.Alffenaar

European Respiratory Journal. 2015,46, 2, p. 444-455  
DOI: 10.1183/09031936.00147014 Published 1 August 2015

Abstract

Multidrug-resistant tuberculosis (MDR-TB) is a major global health problem. The loss of susceptibility to an increasing number of drugs behoves us to consider the evaluation of non-traditional anti-tuberculosis drugs.

Clarithromycin, a macrolide antibiotic, is defined as a group 5 anti-tuberculosis drug by the World Health Organization; however, its role or efficacy in the treatment of MDR-TB is unclear. A systematic review of the literature was conducted to summarise the evidence for the activity of macrolides against MDR-TB, by evaluating *in vitro, in vivo* and clinical studies. PubMed and Embase were searched for English language articles up to May 2014.

Even though high minimum inhibitory concentration values are usually found, suggesting low activity against *Mycobacterium tuberculosis*, the potential benefits of macrolides are their accumulation in the relevant compartments and cells in the lungs, their immunomodulatory effects and their synergistic activity with other anti-TB drugs.

A future perspective may be use of more potent macrolide analogues to enhance the activity of the treatment regimen.